Variables | Controls | 0 Week | 6 Weeks | 12 Weeks | |||
---|---|---|---|---|---|---|---|
Responders | Nonresponders | Responders | Nonresponders | Responders | Nonresponders | ||
DAS28 | — | 5.94 (5.11–6.17) | 4.65b (3.33–5.23) | 3.71c (2.79–4.45) | 3.93 (3.14–4.50) | 3.00 c (2.23–3.67) | 3.90b (2.81–4.90) |
CRP | — | 11.1 (2.6–16.6) | 8.4 (1.4–15.1) | 4.4 (1.3–7.9) | 4.4 (1.5–10.4) | 3.7 (2.1–5.6) | 7.5 (2.7–11.6) |
CD3 MAFC | 18.3 (14.7–22.9) | 18.9 (14.0–25.2) | 23.5b (17.1–33.7) | 17.1 (12.3–22.6) | 22.7b (16.7–29.2) | 18.3 (15.7–24.2) | 25.2 (15.9–30.7) |
CD3 MAFMRP | 3.1 (1.2–5.7) | 4.8 (0.0–8.0) | 5.7 (2.2–8.0) | 2.2 (0.0–7.9) | 8.4b (2.1–11.3) | 5.7 (3.7–8.5) | 7.7a (4.0–11.6) |
CD3 MAFMDR | 14.6 (12.5–18.1) | 12.9 (11.0–16.7) | 19.1b (11.2–24.0) | 12.4 (11.2–15.4) | 15.8b (14.3–18.7) | 12.5 (9.2–17.5) | 13.6 (6.0–20.0) |
CD3 MAFBCRP | 2.5 (0.8–5.7) | 3.1 (0.0–4.4) | 5.0 (2.0–8.0) | 2.0 (0.0–5.5) | 3.9 (2.5–10.7) | 1.4 (0.0–4.3) | 4.5 (1.8–5.8) |
CD19 MAFC | 12.8 (8.9–17.9) | 15.1 (8.1–22.1) | 20.6 (13.5–31.0) | 13.2 (9.3–20.4) | 17.6 (11.4–27.2) | 17.4 (13.1–22.3) | 17.6 (9.2–25.9) |
CD19 MAFMRP | 2.2 (0.0–6.3) | 0.9 (0.0–7.7) | 4.4 (0.0–5.8) | 0.6 (0.0–5.1) | 6.8b (0.5–9.6) | 3.2 (0.3–6.8) | 5.1 (1.9–10.9) |
CD19 MAFMDR | 9.9 (8.0–14.0) | 11.1 (6.0–16.3) | 15.7 (8.4–25.4) | 11.4 (5.3–14.8) | 13.6 (8.6–17.7) | 14.0 (7.1–17.7) | 8.8 (1.9–15.7) |
CD19 MAFBCRP | 3.8 (1.0–6.3) | 3.1 (0.7–7.0) | 4.5 (0.0–11.0) | 2.7 (0.0–5.2) | 5.0 (3.1–8.4) | 2.9 (1.3–5.1) | 3.0 (1.8–3.7) |
Data are expressed as median (IQR). P < 0.05.
↵a versus control,
↵b versus responder,
↵c versus 0-week value. MDR: multidrug resistance; RA: rheumatoid arthritis; DAS28: 28-joint count Disease Activity Score; CRP: C-reactive protein; MAFC: composite multidrug activity factor (of MRP1 and MDR1 activity); MAFMRP: multidrug activity factor of multidrug resistance protein 1; MAFMDR: MAF of multidrug resistance 1; MAFBCRP: MAF of breast cancer resistance protein.